Dr. Anders Lilja is VP Technical Development at Hookipa. He is responsible for developing Hookipa’s groundbreaking science – from initial research, through development of promising candidates to manufacturing of the final product. While at Hookipa, he led the preclinical characterization and manufacturing of our cytomegalovirus vaccine candidate HB-101. Prior to joining Hookipa, he was a Research Investigator and Associate Research Project Leader at Novartis Vaccines. Dr. Lilja holds an MSc in chemical engineering from Chalmers University of Technology, Sweden, a PhD in Biochemistry from University of Maryland, and did postdoctoral training in molecular virology at Princeton University. He has co-authored several publications characterizing key cytomegalovirus vaccine antigens.